Figure 7
From: Intradermal delivery of STAT3 siRNA to treat melanoma via dissolving microneedles

In vivo effect of PEI/STAT3 siRNA loaded with dissolving microneedles on melanoma. (a) Schematics of different administration protocols. (b) The average tumor volume versus time. The tumor volume of G2, G3, G4, or G5 was keeping significant smaller than that of G1 from the time point of day 9 to the termination of day 13 (*P < 0.05 at time point of day 9, and 10, and **P < 0.01 at time point of day 11 and 13), and at time of day 8, the tumor volume of G3 or G5 significant smaller than that of G1 (P < 0.05). However, there was no significant difference between G2, G3, and G4 from the time point of day 9 to the termination of day 13. The tumor volume of G5 was further significantly smaller than that of G2, G3, or G4 (P < 0.01) (mean ± SD, n = 6; n = 6), (c) Tumor weight was compared at the end of experiment (mean ± SD, n = 6, **P < 0.01). (d) Body weight was determined at the end of experiment (mean ± SD, n = 6, **P < 0.01). (e) In vivo STAT3 gene silencing efficiency determined with RT-PCR (n = 3). (f) HE staining of representative tumor tissue from different groups. The tumor necrosis was outlined with black dotted lines.